Scientific Publications
2023
Authors: Joseph Mejia, MD / Lise Kjems, PhD, MD / Rebecca Fine / Caroline Hastings, MD
2022
Authors: Caroline Hastings, MD / Benny Liu, MD / Bryan Hurst / Gerald F. Cox, MD, PhD / Sharon Hrynkow, PhD
-
-
- NNPDF/INPDA Annual Meeting, Orlando, FL
- Caroline Hastings, MD / Lise Kjems, MD, PhD
- July 30, 2022
-
-
-
- World Orphan Drug Congress USA 2022
- Lise Kjems, MD, PhD
- July 13, 2022
-
2021
-
-
- Australian NPC Disease Foundation Annual Conference
- Julian Raiman, MD
- June 25, 2021
-
Results from Phase 1 study to evaluate the single- and multiple-dose pharmacokinetics of Intravenous Trappsol® Cyclo ™ in patients with Niemann Pick Disease type C1 and the Effects of Dosing upon Biomarkers of NPC Disease
-
-
- Australian NPC Disease Foundation Annual Conference
- Caroline Hastings, MD
- June 25, 2021
-
-
-
- Australian NPC Disease Foundation Annual Conference
- Gerald Cox, MD, PhD
- June 25, 2021
-
A phase I/II Study to Evaluate the Safety and Pharmacokinetics of Intravenous Trappsol® Cyclo™ Versus Placebo in Patients With Niemann-Pick Disease Type C (NPC1) and the Pharmacodynamic Effects of Treatment upon Markers of Cholesterol Metabolism and Clinical Outcomes (NCT02912793)
-
-
- WORLDSymposium presentation
- Julian Raiman, MD
- Feb 9, 2021
-
-
- WORLDSymposium presentation
- Caroline Hasting, MD
- Feb 9, 2021

2020
Interim Analysis of Phase I/II Trial with Trappsol® Cyclo™ Delivered Intravenously in NPC Patients
-
- NNPDF Presentation
- Julian Raiman, MD
- Jul 9, 2020
Top Line Results of Phase I Intravenous Trial for NPC
-
- NNPDF Presentation
- Caroline Hasting, MD
- Jul 9, 2020
Trappsol® Cyclo™ is not currently approved for any indication.
Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.